's Daily Biotech Pulse: Gemphire On Fire,...


Gemphire Therapeutics Inc said its gemcabene evaluated in a Phase 2b study dubbed INDIGO-1 for treating sever hypertriglyceridemia demonstrated statistically significant lowering of triglycerides. Secondary endpoints of statistically significant reductions in serum LDL cholesterol, non-HDL cholesterol, VLDL cholesterol, apoB, apoE, apoCIII, and SAA were also met.



from Biotech News